Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis
Author:
Affiliation:
1. AbbVie Inc.; North Chicago IL USA
2. Fort Healthcare; Fort Atkinson WI USA
Funder
AbbVie
Publisher
Wiley
Subject
Infectious Diseases,Dermatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.13884/fullpdf
Reference18 articles.
1. The effect of severe psoriasis on the quality of life of 369 patients;Finlay;Br J Dermatol,1995
2. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey;Krueger;Arch Dermatol,2001
3. Severe psoriasis-oral therapy with a new retinoid;Fredriksson;Dermatologica,1978
4. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial;Menter;J Am Acad Dermatol,2008
5. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL;Gordon;J Am Acad Dermatol,2012
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus;Autoimmunity Reviews;2024-07
2. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13
3. Obesity and novel management of inflammatory bowel disease;World Journal of Gastroenterology;2023-03-28
4. Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial;Journal of Investigative Dermatology;2022-09
5. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial;American Journal of Clinical Dermatology;2022-08-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3